JP2008523083A5 - - Google Patents

Download PDF

Info

Publication number
JP2008523083A5
JP2008523083A5 JP2007545628A JP2007545628A JP2008523083A5 JP 2008523083 A5 JP2008523083 A5 JP 2008523083A5 JP 2007545628 A JP2007545628 A JP 2007545628A JP 2007545628 A JP2007545628 A JP 2007545628A JP 2008523083 A5 JP2008523083 A5 JP 2008523083A5
Authority
JP
Japan
Prior art keywords
antagonist
target
multispecific
targets
inflammatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007545628A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008523083A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/044446 external-priority patent/WO2006063150A2/en
Publication of JP2008523083A publication Critical patent/JP2008523083A/ja
Publication of JP2008523083A5 publication Critical patent/JP2008523083A5/ja
Pending legal-status Critical Current

Links

JP2007545628A 2004-12-08 2005-12-08 炎症性疾患および免疫調節不全疾患、感染性疾患、病的血管新生およびがんの免疫療法および検出のための方法および組成物 Pending JP2008523083A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63407604P 2004-12-08 2004-12-08
PCT/US2005/044446 WO2006063150A2 (en) 2004-12-08 2005-12-08 Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012248395A Division JP2013079240A (ja) 2004-12-08 2012-11-12 炎症性疾患および免疫調節不全疾患、感染性疾患、病的血管新生およびがんの免疫療法および検出のための方法および組成物

Publications (2)

Publication Number Publication Date
JP2008523083A JP2008523083A (ja) 2008-07-03
JP2008523083A5 true JP2008523083A5 (cg-RX-API-DMAC7.html) 2009-02-12

Family

ID=36578580

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007545628A Pending JP2008523083A (ja) 2004-12-08 2005-12-08 炎症性疾患および免疫調節不全疾患、感染性疾患、病的血管新生およびがんの免疫療法および検出のための方法および組成物
JP2012248395A Pending JP2013079240A (ja) 2004-12-08 2012-11-12 炎症性疾患および免疫調節不全疾患、感染性疾患、病的血管新生およびがんの免疫療法および検出のための方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012248395A Pending JP2013079240A (ja) 2004-12-08 2012-11-12 炎症性疾患および免疫調節不全疾患、感染性疾患、病的血管新生およびがんの免疫療法および検出のための方法および組成物

Country Status (6)

Country Link
US (7) US8420783B2 (cg-RX-API-DMAC7.html)
EP (1) EP1819731A4 (cg-RX-API-DMAC7.html)
JP (2) JP2008523083A (cg-RX-API-DMAC7.html)
AU (1) AU2005313971B2 (cg-RX-API-DMAC7.html)
CA (1) CA2587143C (cg-RX-API-DMAC7.html)
WO (1) WO2006063150A2 (cg-RX-API-DMAC7.html)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7148038B2 (en) * 2001-10-16 2006-12-12 Raven Biotechnologies, Inc. Antibodies that bind to cancer-associated antigen CD46 and methods of use thereof
WO2006063150A2 (en) * 2004-12-08 2006-06-15 Immunomedics, Inc. Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
US20070099239A1 (en) * 2005-06-24 2007-05-03 Raymond Tabibiazar Methods and compositions for diagnosis and monitoring of atherosclerotic cardiovascular disease
HUE026303T2 (hu) 2005-07-25 2016-06-28 Emergent Product Dev Seattle B-sejt csökkentés CD37-specifikus és CD20-specifikus kapcsoló molekulák alkalmazásával
MX2008015524A (es) 2006-06-12 2009-01-13 Trubion Pharmaceuticals Inc Proteinas de union multivalentes monocatenarias con funcion efectora.
CA2667808A1 (en) * 2006-11-02 2008-05-15 Seattle Genetics, Inc. Methods of treating neoplastic, autoimmune and inflammatory diseases
SG10201608952QA (en) * 2007-06-07 2016-12-29 Genentech Inc C3b antibodies and methods for the prevention and treatment of complement- associated disorders
US20110142837A1 (en) * 2007-07-20 2011-06-16 Trustees Of The University Of Pennsylvania Method Of Treating Acute Respiratory Distress Syndrome
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
US8557243B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
US8557242B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
EA201500156A3 (ru) 2008-01-03 2017-09-29 Дзе Скриппс Рисерч Инститьют Доставка антител посредством модульного домена распознавания
US8940299B2 (en) * 2008-02-28 2015-01-27 Case Western Reserve University Method of treating cancer
AU2009234277B2 (en) 2008-04-11 2014-12-04 Aptevo Research And Development Llc CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
NZ588674A (en) 2008-05-05 2013-02-22 Novimmune Sa Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
EP2310410A2 (en) * 2008-07-02 2011-04-20 Emergent Product Development Seattle, LLC Tnf- antagonist multi-target binding proteins
US20100278829A1 (en) * 2009-02-06 2010-11-04 Edwards Iii Carl Keith Dual inhibition of immunophilin/cyclophilin family members and emmprin immunoglobulin receptor superfamily members
CN102597005A (zh) * 2009-06-23 2012-07-18 阿雷克森制药公司 与补体蛋白质结合的双特异性抗体
CN102741288B (zh) 2009-08-29 2015-08-19 Abbvie公司 治疗用dll4结合蛋白
WO2011100271A2 (en) * 2010-02-09 2011-08-18 Glaxosmithkline Llc Novel uses
KR101853278B1 (ko) 2010-03-02 2018-05-02 애브비 인코포레이티드 치료학적 ｄｌｌ４ 결합 단백질
WO2012009705A1 (en) 2010-07-15 2012-01-19 Zyngenia, Inc. Ang-2 binding complexes and uses thereof
JP2013537415A (ja) 2010-08-03 2013-10-03 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリンおよびその使用
WO2012162561A2 (en) 2011-05-24 2012-11-29 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
WO2012163521A1 (en) * 2011-05-27 2012-12-06 Dutalys Removal of monomeric targets
JP2013040160A (ja) * 2011-07-01 2013-02-28 Genentech Inc 自己免疫疾患を治療するための抗ｃｄ８３アゴニスト抗体の使用
EP2791101B1 (en) * 2011-12-12 2019-09-18 Vascular Biogenics Ltd. Treatment of non-alcoholic steatohepatitis
ES2749200T3 (es) 2012-05-10 2020-03-19 Bioatla Llc Anticuerpos monoclonales multiespecíficos
WO2014028862A1 (en) 2012-08-17 2014-02-20 Cornell University Use of dna in circulating exosomes as a diagnostic marker for metastasic disease
EP2912065A4 (en) 2012-10-25 2016-10-19 True North Therapeutics Inc ANTI COMPLEMENT C1S ANTIBODIES AND USES THEREOF
RU2015119641A (ru) * 2012-10-26 2016-12-20 Дойчес Ройма-Форшунгсцентрум Берлин Биспецифические аффинные реагенты для нейтрализации специфичных для клеточных линий tnf-альфа
KR20210111353A (ko) 2012-11-01 2021-09-10 애브비 인코포레이티드 항-ｖｅｇｆ／ｄｌｌ4 이원 가변 도메인 면역글로불린 및 이의 용도
RS63212B1 (sr) 2012-11-02 2022-06-30 Bioverativ Usa Inc Antikomplementna c1s antitela i njihove primene
MX2015010023A (es) 2013-02-01 2017-11-17 Transbio Ltd Anticuerpos anti-cd83 y su uso.
EP2774930A1 (en) 2013-03-07 2014-09-10 Aptenia S.R.L. Metallocene compounds and labeled molecules comprising the same for in vivo imaging.
US10494675B2 (en) 2013-03-09 2019-12-03 Cell Mdx, Llc Methods of detecting cancer
HK1220253A1 (zh) 2013-03-09 2017-04-28 Harry Stylli 诊断前列腺癌症的方法
EA201890895A1 (ru) 2013-03-15 2019-02-28 Зинджения, Инк. Мультивалентные и моновалентные мультиспецифические комплексы и их применение
EP2997045A4 (en) * 2013-05-15 2016-11-23 Annexon Inc ANTI-FACTOR C1S ANTIBODIES OF THE COMPLEMENT AND USES THEREOF
SG10201710758PA (en) 2013-07-09 2018-02-27 Annexon Inc Anti-complement factor c1q antibodies and uses thereof
US9416197B2 (en) 2013-11-01 2016-08-16 Ibc Pharmaceuticals, Inc. Bispecific antibodies that neutralize both TNF-α and IL-6: novel therapeutic agent for autoimmune disease
WO2015153732A2 (en) 2014-04-01 2015-10-08 Cornell University Use of double-stranded dna in exosomes: a novel biomarker in cancer detection
WO2015200260A1 (en) * 2014-06-24 2015-12-30 Immunomedics, Inc. Anti-histone therapy for vascular necrosis in severe glomerulonephritis
US10351621B2 (en) 2014-06-24 2019-07-16 Immunomedics, Inc. Anti-histone therapy in acute kidney injury
WO2016025202A1 (en) * 2014-08-14 2016-02-18 The Regents Of The University Of Colorado Antibody-sirna conjugates and uses therefor
EP3693742B1 (en) 2014-09-11 2022-04-06 Harry Stylli Methods of detecting prostate cancer
US11397182B2 (en) 2014-10-07 2022-07-26 Cornell University Methods for prognosing and preventing metastatic liver disease
ES3013108T3 (en) 2014-11-05 2025-04-11 Annexon Inc Humanized anti-complement factor c1q antibodies and uses thereof
US9771385B2 (en) 2014-11-26 2017-09-26 Vascular Biogenics Ltd. Oxidized lipids
CA2968790A1 (en) 2014-11-26 2016-06-02 Vascular Biogenics Ltd. Oxidized lipids and treatment or prevention of fibrosis
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
IL297418B2 (en) 2015-02-18 2023-11-01 Enlivex Therapeutics Rdo Ltd Combined immunotherapy and cytokine control therapy for cancer treatment
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
HK1259251A1 (zh) 2015-04-06 2019-11-29 Bioverativ Usa Inc. 人源化抗c1s抗体及其使用方法
AU2016250570B2 (en) 2015-04-21 2021-07-01 Enlivex Therapeutics Rdo Ltd Therapeutic pooled blood apoptotic cell preparations and uses thereof
US11971402B2 (en) 2015-04-24 2024-04-30 Cornell University Methods and reagents for determination and treatment of organotropic metastasis
EP4190814A1 (en) 2015-05-29 2023-06-07 Amphivena Therapeutics, Inc. Methods of using bispecific cd33 and cd3 binding proteins
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
BR112018005573A2 (pt) 2015-09-21 2019-01-22 Aptevo Research And Development Llc ?polipeptídeos de ligação a cd3?
WO2017091719A1 (en) 2015-11-24 2017-06-01 Annexon, Inc. Anti-complement factor c1q fab fragments and uses thereof
JP6884155B2 (ja) 2016-02-18 2021-06-09 エンリヴェックス セラピューティクス リミテッド 癌治療のための併用免疫療法及びサイトカイン制御療法
EP3525583B8 (en) 2016-10-12 2025-09-10 Bioverativ USA Inc. Anti-c1s antibodies and methods of use thereof
JP6944701B2 (ja) * 2016-10-21 2021-10-06 国立大学法人山口大学 ＣＤ１１ｂアンタゴニストを含む劇症型急性肺炎治療用組成物
MX2020013606A (es) 2018-06-14 2021-05-27 Bioatla Inc Constructos de anticuerpos multiespecificos.
US20210324076A1 (en) * 2018-10-12 2021-10-21 Amphivena Therapeutics Inc Cd33×cd3 binding proteins for treating inflammatory conditions and diseases
SG11202106525TA (en) 2018-12-24 2021-07-29 Sanofi Sa Multispecific binding proteins with mutant fab domains
MX2021007677A (es) 2018-12-24 2021-12-10 Sanofi Sa Proteinas de union multiespecificas basadas en pseudofab.
MA54945A (fr) 2019-02-12 2021-12-22 Regeneron Pharma Compositions et procédés d'utilisation d'anticorps bispécifiques pour lier un complément et un antigène cible
EP3934615A4 (en) * 2019-03-08 2023-01-25 The Regents Of The University Of California ACNE TREATMENT COMPOSITIONS AND METHODS
US11045546B1 (en) 2020-03-30 2021-06-29 Cytodyn Inc. Methods of treating coronavirus infection
WO2023114763A1 (en) 2021-12-13 2023-06-22 Annexon, Inc. Anti-complement factor c1q antibodies with single binding arms and uses thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5093117A (en) * 1989-01-24 1992-03-03 Baxter International Inc. Compositions and method for the treatment or prophylaxis of sepsis or septic shock
US5256770A (en) * 1990-04-09 1993-10-26 Schering Ag Oxidation resistant thrombomodulin analogs
GB8918232D0 (en) 1989-08-10 1989-09-20 Opal Stephen M Pharmaceutical product for the treatment of septic shock
US5637481A (en) * 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
EP1741779A3 (en) 1993-05-17 2010-03-24 The Picower Institute For Medical Research Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine mediated toxicity
US6645493B1 (en) * 1993-05-17 2003-11-11 The Picower Institute For Medical Research Composition containing anti-MIF antibody
US5830448A (en) * 1994-06-16 1998-11-03 Genentech, Inc. Compositions and methods for the treatment of tumors
NZ288883A (en) 1994-07-11 1998-12-23 Univ Texas Conjugates comprising coagulation factors
US6290948B1 (en) * 1996-05-14 2001-09-18 Smithkline Beecham Corporation Method of treating sepsis and ARDS using chamohine beta-10
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
AU742626B2 (en) * 1998-05-20 2002-01-10 Immunomedics Inc. Therapeutics using a bispecific anti-HLA class II invariant chain X anti-pathogen antibody
US6572856B1 (en) * 1998-09-10 2003-06-03 The University Of Virginia Patent Foundation Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies
AU765585B2 (en) * 1998-09-10 2003-09-25 University Of Virginia Patent Foundation Antibodies to C3b(I) for delivery of diagnostic and therapeutic agents to cancer cells
US7972845B2 (en) * 2000-09-07 2011-07-05 Case Western Reserve University Human antibodies against Pseudomonas aeruginosa LPS derived from transgenic xenomouse
AU2002304329A1 (en) * 2001-03-07 2002-09-19 University Of Lausanne Methods for regulation of immune responses to conditions involving mediator-induced pathology
US20040242851A1 (en) * 2001-06-26 2004-12-02 Zhenping Zhu Bispecific antibodies that bind to vegf receptors
WO2003007971A1 (en) * 2001-07-17 2003-01-30 University Of Virginia Patent Foundation Improved heteropolymer complexes and methods for their use
CN101914158A (zh) * 2002-02-14 2010-12-15 免疫医疗公司 抗cd 20抗体及其融合蛋白和使用方法
US7579000B2 (en) * 2002-05-01 2009-08-25 Bayer Schering Pharma Ag Tissue factor targeted antibodies as anticoagulants
US20060140931A1 (en) * 2002-09-16 2006-06-29 Nehal Mohamed Bispecific molecule comprising an anti-cr1 antibody cross-linked to an antigen-binding antibody fragment
US7541440B2 (en) * 2002-09-30 2009-06-02 Immunomedics, Inc. Chimeric, human and humanized anti-granulocyte antibodies and methods of use
WO2004045512A2 (en) * 2002-11-15 2004-06-03 Genmab A/S Human monoclonal antibodies against cd25
EP1578799B8 (en) * 2002-12-02 2011-03-23 Amgen Fremont Inc. Antibodies directed to tumor necrosis factor and uses thereof
CA2510087C (en) * 2002-12-16 2018-09-04 Medarex, Inc. Human monoclonal antibodies against interleukin 8 (il-8)
EP1578801A2 (en) 2002-12-27 2005-09-28 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
ES2522525T3 (es) * 2003-05-15 2014-11-14 Genentech, Inc. Métodos y composiciones para la prevención y el tratamiento de la sepsis
US20050202010A1 (en) * 2003-08-29 2005-09-15 Giroir Brett P. Method of treatment and bioassay involving macrophage migration inhibitory factor (MIF) as cardiac-derived myocardial depressant factor
AU2004272607B2 (en) * 2003-09-11 2008-11-06 Cornerstone Therapeutics Inc. Monoclonal antibodies against HMGB1
EP1732650A4 (en) * 2004-03-27 2008-06-11 Univ Arizona COMPOSITION AND METHOD FOR CANCER TREATMENT
WO2006063150A2 (en) * 2004-12-08 2006-06-15 Immunomedics, Inc. Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
JP5214252B2 (ja) * 2005-03-03 2013-06-19 イミューノメディクス、インコーポレイテッド ヒト化ｌ２４３抗体
CA2749501C (en) * 2009-02-13 2017-01-10 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage

Similar Documents

Publication Publication Date Title
JP2008523083A5 (cg-RX-API-DMAC7.html)
Briasoulis et al. The role of inflammation and cell death in the pathogenesis, progression and treatment of heart failure
Koenig et al. Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape
Kew et al. The IKKα-dependent NF-κB p52/RelB noncanonical pathway is essential to sustain a CXCL12 autocrine loop in cells migrating in response to HMGB1
Campbell et al. Therapeutic targeting of the G-CSF receptor reduces neutrophil trafficking and joint inflammation in antibody-mediated inflammatory arthritis
Moore et al. M2 macrophage accumulation in the aortic wall during angiotensin II infusion in mice is associated with fibrosis, elastin loss, and elevated blood pressure
Linke et al. Activated platelets induce an anti‐inflammatory response of monocytes/macrophages through cross‐regulation of PGE2 and cytokines
José et al. Regulation of neutrophilic inflammation by proteinase-activated receptor 1 during bacterial pulmonary infection
WO2006063150A3 (en) Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
JP2017113019A5 (cg-RX-API-DMAC7.html)
JP2022109909A (ja) 胸腺間質性リンパ球新生因子（ｔｓｌｐ）結合性抗体および抗体を使用する方法
Cao et al. Pathogenic and protective role of macrophages in kidney disease
Wu et al. A single-domain antibody inhibits SFTSV and mitigates virus-induced pathogenesis in vivo
JP2014518883A5 (cg-RX-API-DMAC7.html)
Hong et al. Macrophage regulation of graft-vs-host disease
JP2014076062A5 (cg-RX-API-DMAC7.html)
CN107646039B (zh) 具有有效抗hiv活性的双特异性cxcr4-cd4多肽
JP2005512507A5 (cg-RX-API-DMAC7.html)
HRP20191824T1 (hr) Agonistička sredstva za vezivanje tnf receptora
WO2008106980A3 (en) Recombinant antibodies for treatment of respiratory syncytial virus infections
Gianni et al. Complement-mediated microvascular injury and thrombosis in the pathogenesis of severe COVID-19: A review
JP2015526391A5 (cg-RX-API-DMAC7.html)
Yu et al. Ethyl pyruvate attenuated coxsackievirus B3-induced acute viral myocarditis by suppression of HMGB1/RAGE/NF-ΚB pathway
EA201290172A1 (ru) Стабильные полипептиды, вариабельные домены антитела и антагонисты против tnfr1
CN117771365B (zh) 一种抗狂犬病病毒组合单克隆抗体制剂